全人群还是部分人群?加拿大1型糖尿病筛查策略的成本效果比较
本研究采用混合决策树-Markov模型,从加拿大卫生系统视角比较全人群与靶向自身抗体筛查在替代年龄和频率下的成本效果。与基于家族史在2岁和6岁筛查相比,4岁全人群筛查每万名儿童多花费404534加元但多检出35例,增量成本效果比为11383加元/例检出。2岁和6岁全人群筛查每万名儿童多花费462679加元且多检出18例,增量成本为25923加元/例检出。
要点
- 4岁全人群筛查较家族史2岁和6岁筛查每例检出增量成本为11383加元。
- 2岁和6岁全人群筛查较家族史筛查每例检出增量成本为25923加元。
- 仅高危遗传风险婴儿靶向筛查成本更高且检出例数少于全人群筛查。
核心结论
- 全人群筛查比靶向筛查检出更多高危儿童但成本更高,每例检出的增量成本与其他儿科筛查项目相当。
研究设计与样本
- 使用混合决策树-Markov模型,从加拿大卫生系统视角比较六种筛查策略与不筛查。
- 策略按筛查人群(全人群 vs 仅高危遗传风险或家族史)及筛查年龄和频率(4岁一次 vs 2岁和6岁两次)定义。
主要发现
- 与家族史2岁和6岁筛查相比,4岁全人群筛查每万名儿童多花费404534加元且多检出35例,增量成本效果比11383加元/例检出。
- 2岁和6岁全人群筛查每万名儿童多花费462679加元且多检出18例,增量成本25923加元/例检出。
- 仅高危遗传风险婴儿靶向筛查比全人群筛查成本更高且检出例数更少。
临床怎么用
- 全人群筛查可检出更多高危儿童,但需权衡增量成本,决策时可参考每例检出增量成本与其他儿科筛查项目的比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Timely screening for type 1 diabetes can prevent life-threatening diabetic ketoacidosis and offers the opportunity to delay disease onset with emerging disease-modifying therapies. Yet, population-wide screening is costly, raising questions on whether its benefits justify the costs and the optimal age and frequency of screening. This study examined the cost-effectiveness of general population versus targeted autoantibody screening at alternative ages and frequencies. RESEARCH DESIGN AND METHODS: Using a hybrid decision tree-Markov model, this study compared six strategies defined by different populations screened (i.e., general population vs. only groups at high genetic risk or those with a family history), and frequency and age of screening (once at age 4 vs. twice, at ages 2 and 6) versus no screening. Costs were estimated from the Canadian health system perspective, and effectiveness was measured as the number of at-risk children detected. RESULTS: Compared with family history-based screening at ages 2 and 6, general population screening at age 4 cost $404,534 more but detected 35 more cases (per 10,000 children) for an incremental cost-effectiveness ratio of $11,383/case detected. General population screening at ages 2 and 6 cost an additional $462,679 and detected 18 more cases (per 10,000 children) at an incremental cost of $25,923/case detected. Screening targeted at only infants at high genetic risk involved higher costs and detected fewer cases than general population screening. CONCLUSIONS: General population screening detects more at-risk children than targeted approaches but also incurs higher costs. The incremental cost per case detected is comparable to that reported for other pediatric screening initiatives.
引用
- Mital S, Schatz DA, Haller MJ, et al. Everyone or Just Some? Cost-Effectiveness of General Population Versus Targeted Screening Strategies for Type 1 Diabetes in Canada. Diabetes Care. 2026. PMID: 41770120. doi:10.2337/dc25-2248
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。